Metropolis Healthcare $174 million IPO over subscribed
New Delhi: Metropolis Healthcare Ltd's initial public offering (IPO) to raise as much as 12.04 billion rupees ($174.01 million)was oversubscribed 5.8 times at the end of the book-running process, stock exchange data showed on Friday.
Of the 13.7 million shares the Indian diagnostics company intends to sell, promoter Sushil Kanubhai Shah will give up 6.3 million shares, while investor CA Lotus Investments, a unit of U.S.-based private equity firm Carlyle Group, will offload 7.4 million shares.
The IPO includes an anchor portion of about 6 million shares.
Read Also: Metropolis Healthcare gets SEBI nod, moves for Initial Public Offer
Of the remaining shares, investors bid for about 44.6 million shares in the company, or 5.8 times the 7.7 million on offer, as of 0115 GMT.
Interest for Indian equities has seen a rise recently as the country heads for its general elections next week, amid hopes that the current coalition government led by Prime Minister Narendra Modi would return to power, even though investors continued to maintain a cautious stance.
Read Also: Metropolis Healthcare to aim for Rs 2000 crore plus IPO: Report
Over the last month, India's state-owned Rail Vikas Nigam Ltd and the first ever real estate investment trust in India, Embassy Office Parks REIT have seen successful subscriptions.
Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd